JP7275253B2 - Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 - Google Patents

Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 Download PDF

Info

Publication number
JP7275253B2
JP7275253B2 JP2021510499A JP2021510499A JP7275253B2 JP 7275253 B2 JP7275253 B2 JP 7275253B2 JP 2021510499 A JP2021510499 A JP 2021510499A JP 2021510499 A JP2021510499 A JP 2021510499A JP 7275253 B2 JP7275253 B2 JP 7275253B2
Authority
JP
Japan
Prior art keywords
formula
compound
salt
present application
maleate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021510499A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019210511A5 (https=
JP2021532165A (ja
JP2021532165A5 (https=
Inventor
ウェイ チェン
ウービン パン
ジアワン グオ
Original Assignee
スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド filed Critical スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド
Publication of JP2021532165A publication Critical patent/JP2021532165A/ja
Publication of JPWO2019210511A5 publication Critical patent/JPWO2019210511A5/ja
Publication of JP2021532165A5 publication Critical patent/JP2021532165A5/ja
Priority to JP2023023091A priority Critical patent/JP7651198B2/ja
Application granted granted Critical
Publication of JP7275253B2 publication Critical patent/JP7275253B2/ja
Priority to JP2025035420A priority patent/JP2025074350A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021510499A 2018-05-04 2018-05-04 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 Active JP7275253B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023023091A JP7651198B2 (ja) 2018-05-04 2023-02-17 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
JP2025035420A JP2025074350A (ja) 2018-05-04 2025-03-06 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/085617 WO2019210511A1 (zh) 2018-05-04 2018-05-04 一种s1p1受体激动剂的加成盐及其晶型和药物组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023023091A Division JP7651198B2 (ja) 2018-05-04 2023-02-17 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物

Publications (4)

Publication Number Publication Date
JP2021532165A JP2021532165A (ja) 2021-11-25
JPWO2019210511A5 JPWO2019210511A5 (https=) 2022-07-08
JP2021532165A5 JP2021532165A5 (https=) 2022-07-08
JP7275253B2 true JP7275253B2 (ja) 2023-05-17

Family

ID=68387039

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021510499A Active JP7275253B2 (ja) 2018-05-04 2018-05-04 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
JP2023023091A Active JP7651198B2 (ja) 2018-05-04 2023-02-17 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
JP2025035420A Pending JP2025074350A (ja) 2018-05-04 2025-03-06 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023023091A Active JP7651198B2 (ja) 2018-05-04 2023-02-17 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
JP2025035420A Pending JP2025074350A (ja) 2018-05-04 2025-03-06 Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物

Country Status (13)

Country Link
US (3) US11512078B2 (https=)
EP (2) EP4353719B1 (https=)
JP (3) JP7275253B2 (https=)
KR (2) KR20240094023A (https=)
AU (1) AU2018421487B2 (https=)
CA (1) CA3099196A1 (https=)
ES (1) ES2978392T3 (https=)
IL (3) IL312512B2 (https=)
MX (1) MX2020011665A (https=)
NZ (1) NZ770323A (https=)
SG (1) SG11202010969UA (https=)
WO (1) WO2019210511A1 (https=)
ZA (1) ZA202007347B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023062091A (ja) * 2018-05-04 2023-05-02 スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022099155A1 (en) * 2020-11-09 2022-05-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315266A (zh) 2014-08-01 2016-02-10 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型
JP2016530334A (ja) 2013-09-22 2016-09-29 スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド 免疫調節のための化合物及びその使用及びそれを含む医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533058A (ja) * 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
CN105348276B (zh) 2014-08-22 2020-05-26 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法
CN112778290B (zh) 2017-01-11 2022-12-06 苏州康乃德生物医药有限公司 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
NZ770323A (en) * 2018-05-04 2025-12-19 Suzhou Connect Biopharmaceuticals Ltd Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530334A (ja) 2013-09-22 2016-09-29 スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド 免疫調節のための化合物及びその使用及びそれを含む医薬組成物
CN105315266A (zh) 2014-08-01 2016-02-10 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B. D. Anderson, K. P. Flora，最新創薬化学 下巻，1999年09月25日，347-365
平山令明，有機化合物結晶作製ハンドブック，2008年，p.17-23,37-40,45-51,57-65

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023062091A (ja) * 2018-05-04 2023-05-02 スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
JP7651198B2 (ja) 2018-05-04 2025-03-26 スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
JP2025074350A (ja) * 2018-05-04 2025-05-13 スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物

Also Published As

Publication number Publication date
KR20240094023A (ko) 2024-06-24
JP2025074350A (ja) 2025-05-13
ES2978392T3 (es) 2024-09-11
SG11202010969UA (en) 2020-12-30
IL278464A (https=) 2021-03-01
EP4353719B1 (en) 2025-12-24
JP2023062091A (ja) 2023-05-02
KR102672632B1 (ko) 2024-06-07
EP3792258A4 (en) 2021-10-06
EP3792258A1 (en) 2021-03-17
IL278464B1 (en) 2024-06-01
IL323665A (en) 2025-11-01
KR20210019999A (ko) 2021-02-23
US12202822B2 (en) 2025-01-21
MX2020011665A (es) 2021-01-20
US20210230152A1 (en) 2021-07-29
BR112020022429A2 (pt) 2021-02-09
US20250320200A1 (en) 2025-10-16
WO2019210511A1 (zh) 2019-11-07
IL278464B2 (en) 2024-10-01
IL312512A (en) 2024-07-01
JP2021532165A (ja) 2021-11-25
US20230050777A1 (en) 2023-02-16
EP4353719A1 (en) 2024-04-17
IL312512B2 (en) 2026-03-01
IL312512B1 (en) 2025-11-01
ZA202007347B (en) 2021-10-27
EP3792258B1 (en) 2024-02-07
AU2018421487B2 (en) 2024-09-12
JP7651198B2 (ja) 2025-03-26
AU2018421487A1 (en) 2020-12-17
CA3099196A1 (en) 2019-11-07
NZ770323A (en) 2025-12-19
US11512078B2 (en) 2022-11-29

Similar Documents

Publication Publication Date Title
US11286259B2 (en) Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
US20250320200A1 (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
WO2018184185A1 (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
CN116987069B (zh) 呋喹替尼的共晶、其制备方法、组合物和用途
CN104918937A (zh) 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
CN108299412B (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
TWI662031B (zh) １－｛２－氟－４－［５－（４－異丁基苯基）－１，２，４－噁二唑－３－基］－苄基｝－３－吖丁啶羧酸的晶型
CN105461610B (zh) 一种阿普斯特的晶型及其制备方法、药物组合物和用途
RU2822288C2 (ru) Соль присоединения агониста рецептора s1p1 и ее кристаллическая форма и фармацевтическая композиция на ее основе
HK40106546B (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
HK40106546A (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
HK40042284B (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
HK40042284A (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
BR122022025339B1 (pt) Sulfato de agonista de receptor s1p1, forma cristalina do mesmo, seu método de preparação, seu uso, composição farmacêutica que o compreende e método para tratar e/ou prevenir doença mediada pelo receptor s1p1
BR122022025293B1 (pt) Sal de sódio de agonista de receptor s1p1, forma cristalina do mesmo, seu método de preparação, seu uso, composição farmacêutica que o compreende e método para tratar e/ou prevenir doença mediada pelo receptor s1p1
BR112020022429B1 (pt) Forma cristalina do maleato de agonista de receptor s1p1, seu método de preparação, seu uso e composição farmacêutica que o compreende

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201111

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210421

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220630

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220630

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230217

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230217

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230228

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230301

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230502

R150 Certificate of patent or registration of utility model

Ref document number: 7275253

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150